Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration.

ABSTRACT:

Abstract

Polatuzumab vedotin (pola) is a CD79B-targeting antibody-drug conjugate with significant clinical activity in systemic diffuse large B-cell lymphoma. However, the ability of pola to penetrate the blood-brain barrier (BBB) and induce responses in central nervous system (CNS) lymphoma (CNSL) is unknown. Since other antibody-based therapies can partially penetrate the BBB to induce clinical responses in CNSL and other CNS malignancies, we hypothesized that pola would also partially penetrate the BBB, which could support its evaluation in future CNSL clinical trials. To test this hypothesis, we first evaluated the preclinical efficacy of pola in primary and secondary CNSL xenografts, where we observed that pola significantly decreased CNS tumor burden and prolonged survival in

SUBMITTER: Gao L 

PROVIDER: S-EPMC12755979 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature